Jan Medical is a privately held, emerging medical technology company based in Mountain View, Calif. It developed BrainPulse, a novel, non-invasive, portable brain sensing system that captures a physiological signal utilizing cardiac output to measure vasculature and brain tissue conditions. The device is intended as a rapid aid to help diagnose abnormal neurological conditions including concussion and stroke. Clinical work reported in the articles includes a Stanford trial that detected and longitudinally observed sports-related concussion and a UCSF study that detected vasospasm; additional clinical trials in concussion detection and vasospasm are ongoing. Jan Medical plans to use new funding to complete ongoing clinical trials and to pursue a de novo filing with the FDA and CE Mark registration in the EU. The BrainPulse system is an investigational device that has not received FDA clearance and is not commercially available. Jan Medical develops the Nautilus NeuroWave, a portable, non‑invasive brain‑sensing system intended as a rapid aid to diagnose cerebral abnormalities when conventional imaging is ineffective or unavailable. The company says Nautilus is designed to provide simple, reliable monitoring for patients recovering from subarachnoid hemorrhage (SAH) and to detect and track recovery from sports‑related concussion. Jan Medical completed a vasospasm study at UCSF Hospital and has an investigator‑led trial at Stanford investigating concussion applications. The company announced Series B funding efforts and a corporate collaboration with Brainlab to complete two clinical trials and to file two product 510(k)s with the FDA. Jan Medical is privately held and describes the Nautilus system as investigational and limited by U.S. federal law to investigational use. Management states the Series B validates the platform’s potential amid a challenging funding environment. Jan Medical is a privately held medical technology company based in Mountain View, Calif., that has developed a portable brain‑sensing system intended to rapidly diagnose and aid assessment of strokes. The company describes its device as the world’s first and only portable brain sensing system designed to detect stroke within minutes and help distinguish ischemic from hemorrhagic events. Clinical data on the system were disclosed at the annual meeting of the Society of Interventional Radiology, with Dr. Eric Aldrich serving as principal investigator. Jan plans to use new capital to commence and complete two clinical trials and to prepare and file two product 510(k) submissions with the FDA. CEO Paul Lovoi stated the technology could improve triage, speed treatment, lower costs, and reduce patient risk. The Jan Medical system is an investigational device limited by U.S. federal law to investigational use.

Total raised

$11M

Funding rounds

3

Latest round

Series C

Latest activity

Jan 2016